Not independent
Tenure on this board
5.7 yrs
Meeting calendar
SABS · Special meeting · Friday, September 26, 2025
Sab Biotherapeutics Inc
14 nominees · 3 ballot items.
Three proposals will be voted on at the SAB Biotherapeutics, Inc. special meeting: (1) the Series B Nasdaq Conversion Proposal to approve the potential issuance in excess of 19.99% of the Company1s outstanding common stock upon conversion of Series B Preferred Stock (and related warrants) at below the Nasdaq minimum price, which could be deemed a change of control; (2) the Plan Amendment Proposal to approve amendments to the 2021 Omnibus Equity Incentive Plan increasing available shares by 24,180,000 to 31,932,466 and increasing the evergreen capacity from 10,000,000 to 73,750,000; and (3) any other business as may properly come before the meeting.
Market cap
$297M
1Y TSR
+100.9%
Board grade
C
Record date
Aug 25, 2025
Filing
DEF 14A
Meeting concluded · Sep 26, 2025
Follow how the vote landed and what changed on Sab Biotherapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
TO APPROVE THE POTENTIAL ISSUANCE IN EXCESS OF 19.99% OF OUR OUTSTANDING COMMON STOCK UPON THE CONVERSION OF UP TO 2,500,000 SHARES OF SERIES B PREFERRED STOCK AT LESS THAN THE “MINIMUM PRICE” UNDER NASDAQ LISTING RULE 5635(D), AND WHICH MAY BE DEEMED A “CHANGE OF CONTROL” UNDER NASDAQ LISTING RULE 5635(B), PURSUANT TO THE TERMS OF THE CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK GOVERNING THE SERIES B PREFERRED STOCK
ManagementBoard: FORApproval of issuance of common stock upon conversion of Series B Preferred Stock (and related warrants) at a price below Nasdaq Minimum Price and potential change of control; dilution considerations.
- 2
TO APPROVE AN AMENDMENT TO 2021 OMNIBUS EQUITY INCENTIVE PLAN
ManagementBoard: FORAmend the Plan to (i) increase the maximum shares available under the Plan by 24,180,000 to 31,932,466, and (ii) increase the annual evergreen share pool from 10,000,000 to 73,750,000.
- 3
Transact such other business as may properly come before the Special Meeting or any adjournments or postponements thereof.
ManagementBoard: FORTransact any other business that may properly come before the Special Meeting.
Director elections
Nominees on the ballot14
Not independent
Tenure on this board
4.7 yrs
Not independent
Tenure on this board
3.9 yrs
Also a director at
Titan Machinery Inc (TITN)
Independent
Tenure on this board
4.9 yrs
Independent
Tenure on this board
4.7 yrs
Independent
Tenure on this board
4.7 yrs
Independent
Tenure on this board
4.0 yrs
Independent
Tenure on this board
3.3 yrs
Also a director at
Beyond Air Inc (XAIR)
Not independent
Tenure on this board
2.7 yrs
Independent
Tenure on this board
2.6 yrs
Independent
Tenure on this board
2.2 yrs
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Vivo Capital, LLC | 14.9% | 11,420,000 | $44M |
| 2 | Caligan Partners LPActivist | 10.4% | 7,967,207 | $31M |
| 3 | PERCEPTIVE ADVISORS LLC | 8.4% | 6,431,743 | $25M |
| 4 | Commodore Capital LP | 5.8% | 4,401,500 | $17M |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 5.8% | 4,401,500 | $17M |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 4.9% | 3,760,439 | $14M |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.5% | 3,405,553 | $13M |
| 8 | MILLENNIUM MANAGEMENT LLC | 4.0% | 3,032,697 | $12M |
| 9 | Woodline Partners LP | 3.7% | 2,851,791 | $11M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,493,737 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Sab Biotherapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Seer IncSEER
Annual meeting·Jul 28, 2026·$91M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Sab Biotherapeutics Inc 2025 special meeting?
- Sab Biotherapeutics Inc (SABS) holds its 2025 special shareholder meeting on Friday, September 26, 2025.
- What is the record date for the Sab Biotherapeutics Inc 2025 meeting?
- The record date for the Sab Biotherapeutics Inc 2025 meeting is Monday, August 25, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Sab Biotherapeutics Inc's 2025 meeting?
- The board is presenting 14 director nominees at the Sab Biotherapeutics Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Sab Biotherapeutics Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Sab Biotherapeutics Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.